25,26-Dihydroxyvitamin D3
(Synonyms: 25,26-二羟基维生素D3,25,26-Dihydroxycholecalciferol) 目录号 : GC35081
25,26-Dihydroxyvitamin D3是维生素D3代谢物。
Cas No.:29261-12-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
25,26-Dihydroxyvitamin D3(25,26-dihydroxycholecalciferol) is a metabolite of vitamin D3 with intestinal calcium transport activity.IC50 value:Target: VD metaboliteThe biological activity of synthetic 24,25 and 25,26 diOHD3 was studied in vitamin D-deficient rats. The purpose of this study was to investigate the influence of small doses of both metabolites (0.125-0.250 mug) upon intestinal calcium transport and bone calcium mobilization. Both metabolites were able to increase calcium absorption in rats maintained on a calcium-deficient diet, but failed to do it in rats on a normal calcium diet. Bilateral nephrectomy suppressed this effect. The "bone calcium mobilization" of both derivatives was measured in vitamin D and calcium- or phosphorus-deprived rats after one intravenous dose. When serum calcium was initially low, 24,25 and 25,26 diOHD3 increased serum calcium moderately, but the increment was only significant with 24,25 diOHD3. Human Endogenous Metabolite
[1]. DeLuca HF, et al. 25,26-dihydroxycholecalciferol, a metabolite of vitamin D3 with intestinal calcium transport activity. Biochemistry. 1970 Nov 24;9(24):4776-80. [2]. Miravet L, et al. The biological activity of synthetic 25,26-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol in vitamin D-deficient rats. Calcif Tissue Res. 1976 Dec 2;21(3):145-52. [3]. Fraher LJ, et al. Determination of circulating 25,26-dihydroxycholecalciferol in man by radioimmunoassay. Clin Sci (Lond). 1980 Oct;59(4):257-63.
| Cas No. | 29261-12-9 | SDF | |
| 别名 | 25,26-二羟基维生素D3,25,26-Dihydroxycholecalciferol | ||
| Canonical SMILES | C[C@@H]([C@H]1CC[C@@]2([H])/C(CCC[C@]12C)=C/C=C3C(CC[C@H](O)C\3)=C)CCCC(O)(C)CO | ||
| 分子式 | C27H44O3 | 分子量 | 416.64 |
| 溶解度 | DMSO : 100 mg/mL (240.02 mM; Need ultrasonic) | 储存条件 | Store at -20°C,protect from light,stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL |
| 5 mM | 0.48 mL | 2.4002 mL | 4.8003 mL |
| 10 mM | 0.24 mL | 1.2001 mL | 2.4002 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Simultaneous determination of 24,25- and 25,26-Dihydroxyvitamin D3 in serum samples with liquid-chromatography mass spectrometry - A useful tool for the assessment of vitamin D metabolism
J Chromatogr B Analyt Technol Biomed Life Sci 2020 Nov 20;1158:122394.PMID:33091679DOI:10.1016/j.jchromb.2020.122394.
Vitamin D status is typically assessed by the measurement of 25-hydroxyvitamin D (25(OH)D). However, in selected patient groups the sole determination of 25(OH)D has been proven insufficient for this purpose. The simultaneous measurement of additional vitamin D metabolites may provide useful information for a better evaluation of the vitamin D status. Therefore, we developed and validated a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the simultaneous determination of 25(OH)D3, 25(OH)D2, 24,25(OH)2D3 and additionally 25,26(OH)2D3, which was identified with a synthesized pure substance. Pure and deuterated substances were used to prepare calibrators and internal standards for all target metabolites. Pre-analytical sample preparation comprised protein precipitation followed by liquid-liquid-extraction and derivatization with 4-Phenyl-1,2,4-triazole-3,5-dione (PTAD) using 50 µL sample volume. Samples were analyzed on an Agilent HPLC 1260 system equipped with a silica-based Kinetex® 5 µm F5 100 Å core-shell column (150 × 4.6 mm) coupled to a Sciex 4500 mass spectrometer. For all four metabolites, limit of detection (LoD) and limit of quantification (LoQ) ranged from 0.3 to 1.5 nmol/L and 1.0 to 3.1 nmol/L, respectively. Recovery varied between 76.1 % and 84.3 %. Intra- and inter-assay imprecision were <8.6 % and <11.5 %, respectively. The analysis of external and internal quality control samples showed good accuracy for 25(OH)D3, 25(OH)D2, 24(R),25(OH)2D3 and 25,26(OH)2D3. Method comparison studies with human samples that were also analyzed with two other LC-MS/MS methods showed close agreement. Finally, the present method has been shown capable of identifying patients with 24-hydroxylase deficiency, which proves its clinical utility.
23,25-Dihydroxyvitamin D3: a natural precursor in the biosynthesis of 25-hydroxyvitamin D3-26,23-lactone
Proc Natl Acad Sci U S A 1981 Aug;78(8):4805-8.PMID:6975475DOI:10.1073/pnas.78.8.4805.
To elucidate the biosynthesis of 25-hydroxyvitamin D3-26,23-lactone, two known metabolites of 25-hydroxyvitamin D3--23,25-dihydroxyvitamin D3 and 25,26-dihydroxyvitamin D3--were incubated individually with kidney homogenate prepared from vitamin D-supplemented chickens, a preparation known to produce the lactone from 25-hydroxyvitamin D3. The 25-hydroxyvitamin D3-26,23-lactone produced in vitro was then separated, purified, identified, and quantitated by consecutive straight-phase and reverse-phase high-performance liquid chromatography. 23,25-Dihydroxyvitamin D3 is a far better substrate for production of 25-hydroxyvitamin D3-26,23-lactone than is 25,26-Dihydroxyvitamin D3. Production of lactone is highly selective for the natural 23(S)-hydroxy-23,25-dihydroxyvitamin D3 while both epimers of 25,26-Dihydroxyvitamin D3 resulted in small amounts of product comigrating with natural lactone. It appears that 23(S),25-dihydroxyvitamin D3, but not 25,26-Dihydroxyvitamin D3, is a natural precursor in the synthesis of 25-hydroxyvitamin D3-26,23-lactone; this result also implies that the configuration of the lactone at C-23 is S.
Natural 25,26-Dihydroxyvitamin D3 is an epimeric mixture
Proc Natl Acad Sci U S A 1983 Sep;80(17):5286-8.PMID:6577424DOI:10.1073/pnas.80.17.5286.
Radiolabeled 25,26-Dihydroxyvitamin D3 was prepared in vitro by using chicken kidney homogenates and in vivo in rats from [23,24-3H]-25-hydroxyvitamin D3. These compounds were mixed with synthetic (25S)- and (25R)-25,26-dihydroxyvitamin D3, converted to the corresponding (+)-alpha-methoxy-alpha-trifluoromethylphenylacetyl esters, and subjected to high-performance liquid chromatography that separates the derivatized epimers. The radiolabeled 25,26-Dihydroxyvitamin D3 derivatives were a 1:1 mixture of the 25S and 25R isomers. Similarly unlabeled 25,26-Dihydroxyvitamin D3 isolated from the plasma of rats given large amounts of vitamin D3 was shown to be a 1:1 mixture of the S and R isomers. Therefore, naturally occurring 25,26-Dihydroxyvitamin D3 is a mixture of the 25R and 25S isomers and not just the S isomer reported previously.
Measurement of 25,26-dihydroxyvitamin D: importance of the configuration of the C-25 hydroxyl group
Biochemistry 1984 Dec 18;23(26):6920-5.PMID:6543324DOI:10.1021/bi00321a098.
25,26-Dihydroxyvitamin D3 [25,26(OH)2D3] is chemically synthesized as two stereoisomers: 25(R),26(OH)2D3 and 25(S),26(OH)2D3. Both the R and S configurations have been claimed to be the natural form. Previous studies, however, have not considered the possibility that the stereochemical configuration of the C-25 hydroxyl group could affect the binding of 25,26(OH)2D3 to the rat serum binding protein used in assays for the measurement of this metabolite. In our study, a 50% displacement of radiolabeled 25-hydroxyvitamin D3 ([3H]25OHD3) from its initial binding is achieved with 325 fmol/mL 25(R),26(OH)2D3 and 850-1000 fmol/mL 25(S),26(OH)2D3--a difference in potency of approximately 3-fold. The potency of the R isomer in displacing [3H]25OHD3 was similar to that of 25OHD3 or 24(R),25(OH)2D3. When 25,26(OH)2D levels were measured in 12 normal subjects with both the R isomer and the S isomer as standards, the results were 625 +/- 360 fmol/mL 25(R),26(OH)2D3 equiv and 1800 +/- 1130 fmol/mL 25(S),26(OH)2D3 equiv. To determine which stereoisomer is biosynthesized, two types of experiments were performed. In the first, radiolabeled 25,26(OH)2D3 was biosynthesized from [3H]25OHD3 by using chick renal mitochondria and compared to [3H]25OHD3 as a ligand in the rat serum binding protein assay, which was used to measure 25OHD3, 25(R),26(OH)2D3, and 25(S),26(OH)2D3. Initial binding of radiolabeled 25OHD3 and 25,26(OH)2D3 to the binding protein was comparable, as was their displacement by the nonradioactive metabolites, indicating that chick renal mitochondria produce primarily 25(R),26(OH)2D3.(ABSTRACT TRUNCATED AT 250 WORDS)
Identification of 25,26-Dihydroxyvitamin D3 as a rat renal 25-hydroxyvitamin D3 metabolite
Biochemistry 1981 Sep 29;20(20):5865-71.PMID:7295706DOI:10.1021/bi00523a033.
25,26-Dihydroxyvitamin D3 [25,26-(OH)2D3] was unequivocally identified as a major renal microsomal metabolite of 25-hydroxyvitamin D3 in rats fed a vitamin D sufficient diet. The structural assignment was based on a comparison of the high-performance liquid chromatograms of synthetic and in vitro generated 25,26-(OH)2D3 through four different systems, the ultraviolet absorbance and mass spectral characteristics of biological 25,26-(OH)2D3, and the chromatographic and mass spectral characteristics of the sodium metaperiodate cleavage product of the metabolite. The enzymic synthesis of 25,26-(OH)2D3 was inhibited 60--80% by a semipurified goat anti-rat NADPH--cytochrome P-450 reductase. This implicates cytochrome P-450 as the probable terminal oxidase of the 25-hydroxyvitamin D3-26-hydroxylase system. The methodology used to assay rat renal 25-OH-D3-hydroxylases is also discussed.